MODIFICATION
A -- Scientific Research services in support on non-human primate vaccine development for diarrheal disease.
- Notice Date
- 4/8/2016
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of the Navy, Bureau of Medicine and Surgery, U.S. Naval Medical Research Unit - 6 Peru, Unit 3230 Box 343, American Embassy, DPO AA 34031-0343, Lima, Non-U.S., 34031-0343, Peru
- ZIP Code
- 00000
- Solicitation Number
- N44852JHU
- Archive Date
- 4/28/2016
- Point of Contact
- Elsa De LaTorre, Phone: 5116144127
- E-Mail Address
-
Elsa.DeLaTorre.fn@mail.mil
(Elsa.DeLaTorre.fn@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- The Naval Medical Research Unit No. 6 (NAMRU-6) is looking for a public academic institution in the USA with a large trajectory of research in infectious and tropical diseases, that can evaluate subunit vaccine candidates against bacterial pathogens such as Enterotoxigenic E. Coli (ETC), Campylobacter, and Shigella. Individual vaccine candidates are being evaluated using the Aotus nancymae pre-clinical model of diarrhea. Down-selection of the most promising antigens alone or in combination will be chosen for phase I clinical trial in the search of a universal vaccine that can protect the war fighter against traveler's diarrhea. Non-human primate models of human diarrheal diseases caused by ETEC, Shigella and Campylobacter have been developed at NAMRU-6. These models represent a unique asset to test the efficacy of vaccines targeting enteric diseases. A major limitation with these models has been our limited understanding of the pathophysiological processes underlying the development of diarrhea in these monkeys or how they relate to human diarrhea. In addition, identifying correlates of protective immunity in these models have been challenging due to the scarcity of available tools to measure immunogenicity at the mucosal level. In order to overcome these obstacles, we seek advanced expertise in the execution of studies to better understand the pathogenic features of diarrhea in the monkey model and assess their correlation to human diarrhea as well as to optimize immunological assays and evaluate their performance as surrogate markers of mucosal immunity and vaccine efficacy in our diarrheal models. The execution of these efforts requires consultation with experts in the pathogenesis and clinical aspects of diarrheal diseases as well as hiring a highly specialized post-doctoral immunologist who is willing to relocate to Peru. All activities must be carried out with the utmost adherence to all ethical and quality control standards, in order to minimize risk of performance slips and maintain compliance with appropriation of funds and expectations of the sponsor. The period of performance is one year. If capable sources are not identified through this notice, then NAMRU SIX intends to award a sole source contract under the authority of 13.106-1(b)(i) to the JOHNS HOPKINS UNIVERSITY for the requirements of the collaborative effort with NAMRU SIX. Johns Hopkins University possesses capabilities with the technical expertise needed to successfully accomplish this essential requirement. Furthermore, a presence of the requested contract in Peru is required for collaboration and coordination with scientific research. JHU has an established scientific track, through successful publications, scientific laboratories performing diarrheal research, proven technical staff involved with vaccine development and surveillance of diarrheal disease, and a record of working in Peru relating to diarrheal diseases. Over the 10 years of collaborative work with NAMRU SIX, JHU has shown high professional standards and produced only impeccable research work. The pre-solicitation is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statement shall not exceed 5 (8.5 x 11 inch) pages using a font size not smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. Capability statements are due by 12:00 pm local time,13 April, 2016. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: Elsa.delatorre.fn@mail.mil Please use subject line "N44852JHU". Contracting Office address: 3230 Lima Place Washington, DC 20521 - United States
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/cd6f98941b269995421b2fc31578be28)
- Place of Performance
- Address: AV. VENEZUELA CDRA 36 S/N BELLAVISTA-CALLAO, LIMA, Non-U.S., Peru
- Record
- SN04077938-W 20160410/160408234045-cd6f98941b269995421b2fc31578be28 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |